



Susan Chang

USA

Dr Susan Chang is a Professor in the Division of NeuroOncology and specializes in treating adults with brain tumors and is a co-leader for the NeuroOncology Program for the Helen Diller Family Comprehensive Cancer Center. She has a major research focus on the development of novel therapies for patients and has served as the PI on numerous clinical trials. She is a leader on multi-programmatic grants (including NIH funded SPORE and Program Project Grants) that address the integration of physiologic and metabolic imaging with genomic biomarkers to optimize the management of patients with primary brain tumors. Dr Chang is the Director of the NeuroOncology Supportive Care Services and has created novel supportive care programs such as the Gordon Murray Neuro-Oncology Caregiver program and the Sheri Sobrato Brain Tumor Survivorship Program, both developed to enhance the care and quality of life of patients and families.

Topic: Glioblastoma Clinical Trials and RANO 2.0

The Response Assessment in Neuro-Oncology represents the most widely used set of response criteria for diffuse glioma. The original RANO criteria for high grade glioma were developed to address both pseudo-progression issues after initial treatment with radiotherapy and pseudo-response issues following anti-angiogenetic treatments. An updated version (RANO 2.0) published in 2023 had a major change that directly affects clinical trial design in that the scan performed after radiotherapy for glioblastoma (GBM) is now considered the baseline scan for further follow-up, both for research trials and also in the context of clinical care. Incorporation of flair in response assessment in GBM is tailored to the use of antiangiogenic agents, otherwise, this is no longer considered standard. The revised criteria also addresses emerging surgically based interventions that would be expected to induce contrast enhancement, which needs to be considered in the evaluation of efficacy in the study design of these approaches.